Monarch Medical Technologies Hosts Webinar on Adoption of Inpatient Basal/Bolus/Correction Subcutaneous Insulin Therapy

Presenters Dr. Thomas Garthwaite, VP of Diabetes Care at HCA, and Laurel Fuqua, EVP and CCO at Monarch, focus on strategies in optimizing glycemic management.

Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, today announced that the company will host a complimentary webinar, “Beyond Sliding Scale: Closing the Gap Between Current and Optimal Glycemic Management Practices” on February 13, from 1-2 pm EST.

Dr. Thomas Garthwaite, Vice President for Diabetes Care at Healthcare Corporation of America (HCA) and Laurel Fuqua, EVP and Chief Clinical Officer at Monarch, will lead the webinar to discuss the importance of transitioning to the recommended basal/bolus/correction insulin therapy in the inpatient setting and how the use of computerized insulin-dosing algorithms can support adoption. The webinar will feature HCA’s experience in developing and launching a glycemic optimization program using the EndoTool Glucose Management System.

“While basal/bolus/correction insulin protocol is overwhelmingly recommended by experts and relevant specialty societies, many hospitals and physicians still rely on sliding scale insulin therapy,” said Fuqua. “As a result, they are missing an opportunity to improve the quality, safety, and cost of care for their patients with diabetes and hyperglycemia, which commonly represent more than 25% of their inpatient population. This webinar will provide attendees with strategies and lessons learned from first-hand experience in making the transition away from sliding scale.”

The event will be recorded and available for on-demand viewing on the Monarch website 24 hours following the live event.

About Monarch Medical Technologies

Monarch Medical Technologies is the leading provider of electronic systems for inpatient glycemic management. Monarch’s EndoTool Glucose Management System offers personalized dosing recommendations for intravenous and subcutaneous insulin therapy. As a Class II FDA-cleared, patent pending software suite, EndoTool enables more than 200 hospitals to provide unsurpassed patient-specific glycemic control across a broad population of patients, and ultimately deliver better, safer care. For more information, please visit